These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30114661)

  • 1. Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
    Pathania S; Rawal RK
    Eur J Med Chem; 2018 Sep; 157():503-526. PubMed ID: 30114661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
    Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Drug Res (Stuttg); 2018 Sep; 68(9):485-498. PubMed ID: 29433143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
    Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Entries to and Biological Activity of Pyrrolopyrimidines.
    De Coen LM; Heugebaert TS; García D; Stevens CV
    Chem Rev; 2016 Jan; 116(1):80-139. PubMed ID: 26699634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
    Ghith A; Ismail NSM; Youssef K; Abouzid KAM
    Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
    Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
    Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-anilino-4-substituted-7H-pyrrolopyrimidines as PDK1 inhibitors.
    O'Brien NJ; Brzozowski M; Buskes MJ; Deady LW; Abbott BM
    Bioorg Med Chem; 2014 Aug; 22(15):3879-86. PubMed ID: 25012568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors.
    Chung SH; Park J; Lee JW; Song J; Jung D; Min KH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1822-1833. PubMed ID: 32972253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).
    Hawkinson JE; Sinville R; Mudaliar D; Shetty J; Ward T; Herr JC; Georg GI
    ChemMedChem; 2017 Nov; 12(22):1857-1865. PubMed ID: 28952188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
    Ali EMH; Abdel-Maksoud MS; Oh CH
    Bioorg Med Chem; 2019 Apr; 27(7):1159-1194. PubMed ID: 30826188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
    Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
    Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
    Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
    Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.
    Jung MH; Kim H; Choi WK; El-Gamal MI; Park JH; Yoo KH; Sim TB; Lee SH; Baek D; Hah JM; Cho JH; Oh CH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6538-43. PubMed ID: 19857963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
    Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.